Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Licensed medicineStub

Tesamorelin

Stabilized GHRH analogue

A stabilized analogue of growth hormone releasing hormone, licensed in the United States to reduce excess abdominal fat in people with HIV and lipodystrophy.

Reconstitution calculator

At a glance

Licensed medicine

A regulator has licensed it for at least one use, in at least one country. That says nothing about uses outside the license.

This page is a stub

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

How strong is the evidence

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine: Tesamorelin

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies

    First studies in people: safety, and how the body handles it.

  5. Cells and animals

    Laboratory and animal work. An animal result is not a result in people.

97
papers on PubMed
76
of them in people
21
randomized trials
34
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

Handling and reconstitution

From powder to a measured sample

The same four steps for any lyophilized vial. Laboratory handling, not use in a person.

  1. 1. Read the vial

    The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.

  2. 2. Add the diluent

    A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.

  3. 3. Work out the strength

    Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.

  4. 4. Measure the sample

    Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.

The calculator below does the arithmetic and shows its working.

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on Tesamorelin itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Tesamorelin; no amount here is a recommendation.

Tesamorelin: on PubMed

What PubMed held for Tesamorelin on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

97
papers
76
in humans
23
clinical trials
21
randomized trials
2012: 8 papers122013: 5 papers2014: 2 papers142015: 4 papers2016: 5 papers162017: 5 papers2018: 1 papers182019: 5 papers2020: 3 papers202021: 6 papers2022: 5 papers222023: 2 papers2024: 4 papers242025: 4 papers2026: 17 papers so far26
Papers per year, 2012 to 2026. The most in one year: 17.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD

    Randomized trialFourman LT, Billingsley JM, Agyapong G, et al. JCI insight, 2020. PMID 32701508

  2. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors

    Randomized trialRusso SC, Ockene MW, Arpante AK, et al. AIDS (London, England), 2024. PMID 38905488

  3. Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation

    Randomized trialBraun LR, Feldpausch MN, Czerwonka N, et al. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2017. PMID 29031905

  4. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity

    Randomized trialEllis RJ, Vaida F, Hu K, et al. The Journal of infectious diseases, 2025. PMID 39813152

  5. The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH

    Randomized trialMakimura H, Murphy CA, Feldpausch MN, et al. The Journal of clinical endocrinology and metabolism, 2014. PMID 24178787

  6. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials

    Meta-analysisBadran AS, Helal A, Shata KS, et al. Obesity research & clinical practice, 2026. PMID 41545261

  7. Tesamorelin

    Review, 2012. PMID 31644039

  8. Tesamorelin

    StudyGrunfeld C, Dritselis A, Kirkpatrick P Nature reviews. Drug discovery, 2011. PMID 21283099

Search used: ("Tesamorelin"[tiab]). Run it on PubMed

Research links

Also in GH axis

Sold in blends: Retatrutide + Tesamorelin, Tesamorelin + Ipamorelin, Tesamorelin + Ipamorelin + CJC-1295 (No DAC)